Compare Regeneron Pharmaceuticals Inc (REGN) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Toro Company (The) Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $794.49 (market cap $80.14B), while Toro Company (The) Common Stock trades at $99.94 (market cap $9.30B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.6× Toro Company (The) Common Stock's market cap, and Toro Company (The) Common Stock pays the higher dividend (1.59%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Toro Company (The) Common Stock for 0 Days on average.
| REGN | TTC | |
|---|---|---|
Market Cap | $80.14B | $9.30B |
Volume | 878,669 | 420,909 |
Sector | Health | Industrials |
52-Week High | $852.03 | $101.76 |
52-Week Low | $569.17 | $67.99 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $74.85B | $10.20B |
Dividend Yield | 0.48% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $793.01, up 5.3% on the day, approaching its R3 resistance at $792. The stock exhibits strong bullish technical signals and has consistently beaten earnings estimates, with Q2 2026 EPS of $14.29 significantly exceeding the $10.16 forecast. Recent news highlights a major immunology alliance expansion with Sanofi, valued up to $8 billion, providing substantial future revenue potential. Fundamentals remain robust with a 27.86% net income margin and a reasonable P/E of 19.26.
The outlook for REGN is positive, driven by strong earnings momentum and strategic partnerships. Key opportunities include the expanded Sanofi collaboration and promising clinical trial data. Risks involve competitive pressures in key drug markets and execution challenges in integrating new antibody programs. Analyst consensus is strongly bullish with a $856.25 price target, suggesting approximately 8% upside from current levels.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
